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Abstract
PTPRD (protein tyrosine phosphatase, receptor type, D) is a tumor suppressor gene, frequently inactivated
through deletions or epigenetic mechanisms in several cancers with importance for global health. In this study,
we provide new and functionally integrated evidence on genetic and epigenetic alterations of PTPRD gene in
hepatocellular carcinomas (HCCs). Importantly, HCC is the sixth most common malignancy and the third most
common cause of cancer-related mortality worldwide. We used a high throughput single nucleotide poly-
morphism (SNP) microarray assay (Affymetrix, 10K2.0 Assay) covering the whole genome to screen an
extensive panel of HCC cell lines (N = 14 in total) to detect DNA copy number changes. PTPRD expression was
determined in human HCCs by Q-RT-PCR and immunohistochemistry. Promoter hypermethylation was as-
sessed by combined bisulfite restriction analysis (COBRA). DNA methyl transferase inhibitor 5-azacytidine
(5-AzaC) and/or histone deacetylase inhibitor Trichostain A (TSA) were used to restore the expression. We
identified homozygous deletions in Mahlavu and SNU475 cells, in the 5¢UTR and coding regions, respectively.
PTPRD mRNA expression was downregulated in 78.5% of cell lines and 82.6% of primary HCCs. PTPRD
protein expression was also found to be lost or reduced in HCC tumor tissues. We found promoter hy-
permethylation in 22.2% of the paired HCC samples and restored PTPRD expression by 5-AzaC and/or TSA
treatments. In conclusion, PTPRD is homozygously deleted and epigenetically downregulated in HCCs. We
hypothesize PTPRD as a tumor suppressor candidate and potential cancer biomarker in human HCCs. This
hypothesis is consistent with compelling evidences in other organ systems, as discussed in this article. Further
functional assays in larger samples may ascertain the contribution of PTPRD to hepatocarcinogenesis in greater
detail, not to forget its broader importance for diagnostic medicine and the emerging field of personalized
medicine in oncology.
Introduction
Hepatocellular carcinoma (HCC) is the sixth mostcommon malignancy and the third most common cause
of cancer-related mortality worldwide (Ferlay et al., 2010).
HCC is also the most common type of liver cancer and ac-
counts for 85%–90% of primary liver cancers (El-Serag et al.,
2007). Various genetic/epigenetic aberrations and several
chromosomal regions with recurrent gains and losses have
been reported in HCC (Farazi et al., 2006; Liu et al., 2014;
Midorikawa et al., 2006) but the molecular mechanisms un-
derlying the hepatocarcinogenic process are not completely
understood.
Chromosomal deletions and amplifications are large struc-
tural changes that may harbor genes regulating cell proliferation,
apoptosis, genome stability, angiogenesis, invasion, and metas-
tasis (Albertson et al., 2003). Such aberrations can be monitored
with large-scale genomic and molecular genetic technologies,
including single nucleotide polymorphism (SNP) micro-
arrays (Heinrichs et al., 2007). SNP arrays are high-resolution
cytogenetic tools that provide copy number alterations, in-
cluding loss-of-heterozygosity events (Pfeifer et al., 2007).
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In order to find novel chromosomal abnormalities at a
higher resolution, we performed a microarray screen in a
panel of 14 HCC lines. Our SNP array analysis revealed
many chromosomal aberrations, including previously iden-
tified regions (Biden et al., 1997). One of the most remarkable
aberrations was a homozygous deletion at chromosome 9p23
harboring PTPRD gene. PTPRD is one of the 21 human
receptor-type protein tyrosine phosphatases (PTPs) and maps
to 9p23–24.1. PTPs constitute a large family having a total of
107 members with crucial regulatory roles in the cellular
metabolism, and their deregulation has been linked to tu-
morigenesis ( Julien et al., 2011).
Tumor suppressor activity of PTPRD was first suggested
by Urushibara et al. (1998) who showed selective down-
regulation of PTPRD mRNAs in rat primary hepatomas and
HepG2 hepatoblastoma cell line. Tumor suppressive prop-
erties of PTPRD and its prognostic biomarker potential were
also reported in glioblastoma multiforme (GBM), melanoma,
and gastric adenocarcinoma (Solomon et al., 2008; Veeriah
et al., 2009; Wang et al., 2014). PTPRD dephosphorylates and
inactivates STAT3 oncoprotein that regulates cell cycle pro-
gression, apoptosis, and survival mechanisms (Bowman et al.,
2000; Veeriah et al., 2009). Recently, it was reported by an
in vivo study that allelic loss of PTPRD leads to Stat3 hyper-
activation in GBM (Ortiz et al., 2014). PTPRD was also shown
to dephosphorylate and destabilize Aurora kinase A (AURKA)
oncoprotein in neuroblastomas (Meehan et al., 2012).
Homozygous deletions of PTPRD were reported in lung
cancer (1%–11%) (Kohno et al., 2010; Zhao et al., 2005),
cutaneous squamous cell carcinomas (SCC) (17%) (Purdie
et al., 2007), neuroblastoma (12%–50%) (Nair et al., 2008;
Stallings et al., 2006), melanoma (9%) (Stark et al., 2007),
GBM (33%) (Solomon et al., 2008), laryngeal squamous cell
carcinoma (LSCC) (20%) (Giefing et al., 2011), and recently
in human HCC samples (1%–17%) (Guichard et al., 2012;
Nalesnik et al., 2012).
Somatic mutations of PTPRD were also shown in various
cancers with the rate of 4%–21.5% (Sjoblom et al., 2006;
Solomon et al., 2008; Veeriah et al., 2009; Walia et al., 2014;
Weir et al., 2007). In the case of HCC, mutation rates are very
low (1.4%–4%) (Bamford et al., 2004; Guichard et al., 2012).
Furthermore, PTPRD is also silenced frequently by promoter
hypermethylation in colon cancer (50%), GBM (37%),
squamous cell of head and neck (25%), and breast cancer
(20%) (Veeriah et al., 2009).
Although it is widely accepted that PTPRD functions as a
tumor suppressor gene, its involvement in hepatocarcino-
genesis has not been investigated. In this study, we examined
the role of PTPRD in HCC pathogenesis by evaluating its
expression, as well as genetic and epigenetic alterations.
Here, we demonstrate that PTPRD is homozygously deleted
and significantly downregulated in human HCCs. According
to our analysis, this downregulation occurs through the pro-
moter hypermethylation and/or histone deacetylation. Our
results indicate that genetic and epigenetic alterations of
PTPRD may play a role in HCC development.
Materials and Methods
Cell lines and patient samples
HCC-derived cell lines; SNU449, Focus, SNU182, SNU475,
Mahlavu (MV), SNU398, SNU423, SK-Hep1, SNU387, Hep40,
Huh7, PLC/PRF5 (PLC), Hep3B and hepatoblastoma-de-
rived cell line, HepG2, were maintained as described (Acun
et al., 2011). 32 pairs of HCC and tumor-adjacent normal
archival DNA samples had previously been described (Ozturk
et al., 1991). TissueScan Liver Cancer Tissue qPCR Panel I
(Cat. No: LVRT501) was purchased from Origene Technol-
ogies (Rockville, MD). QPCR panel contains pre-normalized
cDNAs obtained from 48 liver samples consisting of 8
tumor-adjacent normal, 23 HCC (grades I, II, IIIA, IV), 3
cholangiocarcinoma, 1 adenoma, and 13 nontumor lesions
of the liver. (Supplementary Table S1; supplementary ma-
terial is available online at www.liebertpub.com/omi). Liver
Tumor Tissue Array (Cat. No: Z7020060) was purchased
from BioChain (BioChain Institute, Inc., Hayward, CA) that
had 96 cores covering 36 cases of all common types of liver
cancers and 12 cases of normal cases and other nonmalig-
nant liver tissues with duplicates (Supplementary Table S2).
Normal liver DNA sample was purchased from BioServe
(Beltsville, MD, USA).
SNP microarray assay
We used 10 K 2.0 SNP microarrays (Affymetrix, 10K2.0
Assay) that contains *10 K SNP markers covering the whole
genome with a mean physical inter-marker distance of 0.2 MB.
Probe preparation for SNP microarray hybridization experi-
ments were done according to manufacturer’s manual. Detailed
information of this method was supplied in supplementary data
(Supplementary Method S1).
Microarray analysis
Primary analysis (e.g., quality control metrics, SNP call-
ing, etc.) were performed with Affymetrix GCOS and GDAS
software bundle. Secondary analysis (e.g., intensity normal-
ization, background correction, etc.) were performed to re-
veal chromosomal abnormalities by using dCHIP-Analyzer
(Li et al., 2001). Model-based expression was selected with
perfect match-mismatch background correction. Normal-
ization was performed according to the median chip intensity
using invariant set and smoothed with running median
method. Hidden Markov Model and median smoothing were
used in inferred copy number analysis.
Multiplex semi-quantitative RT-PCR
Total RNA isolation from the HCC cell lines and fol-
lowing cDNA synthesis were performed by NucleoSpin
RNA II (Macherey-Nagel, Germany) and Revert Aid
(Fermentas, Lithuania) kits, respectively, according to the
manufacturer’s instructions. Multiplex semi-quantitative
RT-PCR was performed with PTPRD-specific PTPRD-
MSQ-F/PTPRD-MSQ-R and GAPDH (glyceraldehyde-
3-phosphate dehydrogenase)-specific GAPDH-MSQ-F/
GAPDH-MSQ-R primer pairs (Supplementary Table S3).
Quantitative real-time RT-PCR (Q-RT-PCR)
Relative quantification of PTPRD transcripts was per-
formed with SYBR Green qPCR kit (Finnzymes DyNAmoTM
HS; Finnzymes, Finland) on Stratagene MX3005PTM real-
time RT-PCR system (Stratagene, La Jolla, CA) as previously
described (Acun et al., 2011). PTPRD-QRT-F/PTPRD-QRT-
R primer pair was used with cDNAs from HCC cell lines and












































liver cancer qPCR panel (Supplementary Table S1). GAPDH
and TBP (TATA box binding protein) genes were used as
internal controls (Fu et al., 2009; Gur-Dedeoglu et al., 2009)
(Supplementary Table S3). Modified DDCt formula was used
to measure the relative levels of PTPRD transcripts (Acun
et al., 2011; Pfaffl et al., 2001). Statistical analysis were per-
formed by Student’s t-test.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on human
liver tumor tissue array (Supplementary Table S2) by using
DAKO Universal Dako LSAB + Kit (Code; K0690) ac-
cording to the manufacturer’s instructions. The intensity of
PTPRD staining for each sample was scored as previously
described (Chen et al., 2006; Oztas et al., 2010). Statistical
analysis were performed by Student’s t-test. Detailed infor-
mation of this method was supplied in supplementary data
(Supplementary Method S2).
Mutation screening
Genomic PCR was applied with two sets of overlapping
primers in order to amplify 20th exon (Supplementary Table
S3). PCR96 Cleanup Kit (Millipore, Billerica, MA) was used to
purify PCR products that were then directly sequenced by a
sequencing service company; Iontek (Istanbul, Turkey). Muta-
tion analysis was performed with Mutation Surveyor software
package (v 3.10, SoftGenetics, LLC, State College, PA).
5-Azacytidine (5-AzaC) and Trichostatin A (TSA)
treatments
5-AzaC (Sigma-Aldrich, St. Louis, MO) and TSA (Sigma-
Aldrich) treatments were performed as described previously
(Acun et al., 2011). In brief, 3 · 105 cells/well were seeded in
6-well plates. After 24 h, 5-AzaC (2.5 lM) treatment was
done for 96 h. TSA treatment (1 lM) was performed in the
last 24 h either alone or in combination with 5-AzaC. Med-
ium and 5-AzaC were replenished every 24 h. At the end of
treatment, cells were harvested for DNA and RNA isolations.
Sodium bisulfite treatment and combined bisulfite
restriction analysis (COBRA)
Qiagen DNeasy Tissue kit (Hilden, Germany) was used to
extract genomic DNA from cell lines. Genomic DNAs were
bisulfite treated by Epigentek MethylampTM DNA Mod-
ification Kit (Brooklyn, NY) according to the manufacturer’s
instructions. Nested primer pairs were designed in order to
amplify the part of PTPRD promoter region containing CpG
island (Supplementary Table S3 and Supplementary Fig. S1).
Amplicons of ptprdBi2F/ptprdBi1R primer pair were re-
striction digested with BstUI (New England BioLabs, Ips-
wich, MA) to analyze methylation status, as previously
described (Xiong et al., 1997).
Results
SNP Microarray and genomic PCR analysis of 14 HCC
cell lines identified homozygous deletions
in the PTPRD locus
Our SNP array screening identified a homozygously de-
leted region in the Mahlavu cell line. This deleted region (*1
Megabase) was spanned by 6 SNPs and mapped to the 5¢UTR
of PTPRD (Fig. 1). We then asked whether other focal de-
letions existed that were not covered by the SNPs of the
microarray. Genomic PCR analysis that uses intronic primers
flanking each coding exon revealed another deletion region in
FIG. 1. Homozygous deletion in Mahlavu cell line revealed by the SNP array is
located in 5¢UTR region of PTPRD gene, between exon 4–exon 9. CN, copy
number; LOH, loss of heterozygosity. Vertical lines represent exons.












































SNU475 cell line between exons 24–31 (*40 Kilobase). All
coding exons were successfully amplified in the remaining 13
HCC cell lines and normal liver sample (Fig. 2, Supple-
mentary Table S3). ENST00000381196 (EnsEMBL release
59, GRCh37) is the Ensembl Transcript ID used for anno-
tating the deletions (Flicek et al., 2012).
Mutation analysis of PTPRD in HCCs identified a SNP
According to the Sanger Institute COSMIC (Catalogue of
Somatic Mutations in Cancer) database, exon 20 is the most
mutated exon (14%) (Bamford et al., 2004). Moreover, three
different mutations were recently described in this exon
(Solomon et al., 2008). Therefore, we genotyped exon 20 in
HCC cell lines and archival HCC samples. We identified a
SNP (rs10977171, Q447E) in SNU182 HCC cell line and in
one HCC sample (C12) (Supplementary Fig. S2).
PTPRD expression is downregulated in HCC cell lines
We measured PTPRD mRNA expression in 14 HCC cell
lines by Q-RT-PCR (Fig. 3). PTPRD transcript was found to
be low in Mahlavu, PLC, SNU398, SNU475, and almost
undetectable in Focus, HepG2, Hep3B, Huh7, SNU182,
SNU387, and SNU423 cells. Hep40, SK-Hep1, and SNU449
cells showed robust PTPRD mRNA expression. These results
suggested that PTPRD expression is negatively regulated in
some HCC cells by as yet unidentified mechanisms.
PTPRD expression is reduced in human HCC samples
We expanded our analysis to clinical samples and inves-
tigated PTPRD mRNA levels in a panel of HCC samples by
Q-RT-PCR. We found strong reduction of PTPRD expres-
sion in 19 of 23 (82.6%) primary HCCs (GI, GII, GIIIA, GIV)
FIG. 2. Homozygous deletion in SNU475 cell line (between exon 24–exon 31)
shown by genomic PCR. [(-) control]: DNA-free PCR mixture. Vertical lines rep-
resent exons.
FIG. 3. Q-RT-PCR analysis of PTPRD in HCC cell lines. GAPDH was used as an
internal control. Experiments were conducted twice, and standard deviations are
indicated.












































compared to eight normal liver tissues from the same panel (P
value = 0.013; Fig. 4).
PTPRD protein is missed or downregulated in HCCs
We performed immunohistochemistry in the human liver
tumor tissue arrays to investigate if the PTPRD protein levels
were also lower in tumor samples (Fig. 5, Supplementary
Table S2). PTPRD expression was localized to the cytoplasm
in all cases and differential expression was observed between
tumoral and non-tumoral liver tissues. Most of the grade III
tumor cases (85.7%) failed to express the PTPRD protein. On
the other hand, all non-tumoral liver tissues stained either
moderately (33.3%) or strongly (66.7%) (Fig. 5 and Table 1).
PTPRD promoter is methylated in primary HCC samples
We sought CpG islands in the promoter region of PTPRD
(Veeriah et al., 2009) by using MethPrimer software (Li et al.,
2002) and described a CpG island near transcription initiation
site (Fig. 6). Then, we analyzed this CpG island in archival
HCC samples by COBRA method to determine its methyl-
ation level (Supplementary Fig. S1). In 6 out of 27 (22.2%)
normal-tumor pairs, tumors had high level of methylation
(Fig. 7, Supplementary Fig. S3).
PTPRD expression is restored by 5-AzaC and TSA
The Hep3B cell line has no described PTPRD locus de-
letions or hot-spot mutations, but it has lower PTPRD ex-
pression at the mRNA level. A low expression pattern could
be due to epigenetic mechanisms in the form of promoter
hypermethylation and/or histone deacetylation (Cameron
et al., 1999). To test this hypothesis, we treated cells with
DNA methyl transferase inhibitor (5-AzaC) and/or histone
deacetylase inhibitor (TSA) (Fig. 8) and successfully restored
the PTPRD expression in the treated cells. Besides, we ob-
served similar results in PLC cells (data not shown).
Discussion
In this study, we examined the putative DNA copy number
changes in the genomic DNAs of 14 HCC cell lines using
SNP microarrays in order to identify genetic loci that are
involved in hepatocarcinogenesis. We observed several copy
number gains (on chromosomes 8, 9, 12, 14, 15, 16, 17, 19,
22, and X) and three homozygous deletions (on chromosomes
9, 13, and X). We excluded LOH profiles based on genotype
calls due to the cell line’s nature. The cell lines used in this
study were hyperploid; therefore using genotyping calls as a
qualitative marker would be erroneous.
There were two distinct interstitial regions of deletions on the
short arm of chromosome 9 localized at 9p22.1–p21.2 and 9p23.
The 9p22.1–p21.2 region harbors important tumor suppressor
locus of cyclin-dependent kinase inhibitor 2 (CDKN2) that has
been shown to be frequently inactivated in HCC (Biden et al.,
1997). Concerning 9p23, PTPRD localizes at this region that
is frequently deleted in various tumors (Giefing et al., 2011;
Guichard et al., 2012; Kohno et al., 2010; Nair et al., 2008;
Nalesnik et al., 2012; Purdie et al., 2007; Solomon et al.,
2008; Stallings et al., 2006; Stark et al., 2007; Zhao et al.,
2005). Interestingly, a recent in vivo study has shown that
heterozygous loss of Ptprd is sufficient to promote tumor-
igenesis, and co-deletion of Ptprd and Cdkn2a accelerate
tumorigenesis in mice (Ortiz et al., 2014).
Our results provide a comprehensive genome-wide copy-
number profile of the most commonly used 14 HCC cell lines
and showed deletions in 2 out of 14 HCC cell lines, Mahlavu
and SNU475, in 5¢UTR and coding region, respectively (Fig.
1, Fig. 2). The Sanger CONAN (Copy Number Analysis)
database showed the same exonic deletion in SNU475 cell
line, but among the 14 HCC cell lines that we analyzed, seven
cell lines (Mahlavu, SNU398, Focus, SNU182, Hep40,
HepG2, and Hep3B) are absent in this database (Bamford
et al., 2004). Recently, two deletions were described in an
intronic region (between exons 24–25) and 5¢UTR region
(between exons 7–9), in 17% and 0.08% of HCC samples,
respectively (Guichard et al., 2012; Nalesnik et al., 2012).
Since many tumor suppressor genes are silenced during
carcinogenesis, we investigated PTPRD mRNA levels in
HCC cell lines and found low or undetectable expression in
11 out of 14 cell lines (Fig. 3). We than extended this study to
clinical samples and observed that 82.6% primary HCCs
were displaying low PTPRD mRNA expression. Our results
FIG. 4. PTPRD expression in HCC tumors relative to normal tissues was analyzed
by Q-RT-PCR. Relative mRNA levels normalized to TBP are represented. Patients
are grouped depending on tumor stage (GI–GIV). Clinicopathological characteristics
of patients (C9-E9) are listed in Supplementary Table S1.












































Table 1. Immunostaining of Human Liver Tissues with PTPRD Antibody
PTPRD expression (staining intensity)
(-) + + + + + +
Pathological diagnosis Negative Weak Moderate Strong
Hepatocellular carcinoma (HCC) (n = 25)
HCC grade I (n = 6) 6 (100%)
HCC grade II (n = 12) 2 (16.7%) 2 (16.7%) 8 (66.7%)
HCC grade III (n = 7) 6 (85.7%) 1 (14.3%)
Clear cell carcinoma (n = 3) 1 (33.3%) 1 (33.3%) 1 (33.3%)
Bile duct carcinoma (n = 4) 4 (100%)
Metastatic adenocarcinoma (n = 3) 3 (100%)
Undifferentiated sarcoma (n = 1) 1 (100%)
Non-tumoral liver tissues (n = 12)
Normal liver (n = 3) 3 (100%)
Chronic viral hepatitis (n = 1) 1 (100%)
Cellular swelling (n = 2) 2 (100%)
Viral subfulminant hepatitis (n = 2) 1 (50%) 1 (50%)
Viral hepatitis related cirrhosis (n = 3) 1 (33.3%) 2 (66.7%)
Hemangioma (n = 1) 1 (100%)
Staining intensities expressed as ( - ): negative, + : weak, ++ : moderate, +++ : strong.
Numbers represent counts of stained cases in each group.
FIG. 5. PTPRD protein expression in human liver
tissues. Representative photographs from PTPRD im-
munohistochemistry study performed in non-tumoral
and tumoral human liver tissues. Normal liver tissue
shows strong, uniform cytoplasmic staining (brown)
throughout the tissue. Expression was lost in tumoral
liver tissues (grade II and III) (Scale Bars: 100 lm).












































FIG. 7. Methylation analysis of PTPRD promoter region by COBRA. Photograph
is representative of COBRA method results. Promoter region was amplified and
Normal–Tumor paired amplicons were cut with BstUI restriction enzyme. M,
marker; N, normal; T, tumor.
FIG. 6. CpG island at promoter region of the PTPRD gene is shown as light blue
area in the graph. Primers used for the analysis of methylation status are indicated as
arrows. Red vertical lines denote CpG sites, numbered boxes denote exons, and
‘‘TIS’’ denotes the transcriptional start site.












































show that downregulation of PTPRD was not restricted to the
cell lines but also occurred in vivo (Fig. 4).
Immunohistochemical analysis confirmed the reduction
of PTPRD in HCCs at the protein level. There is a signifi-
cant difference between normal (non-tumoral) and HCC
samples according to their PTPRD expression profile (P
value = 0.0002; Table 1). Moreover, there is a tendency to-
wards a lower expression of PTPRD in cancer samples with
higher grades compare to lower grades, which may indicate
PTPRD’s prognostic value in HCCs.
Although tumor suppressor genes are commonly in-
activated by loss-of-function mutations in cancer, somatic
PTPRD mutations in HCCs have been reported with very low
rates (1.4%–4%) (Bamford et al., 2004; Guichard et al.,
2012), which is consistent with our observation. Our targeted
mutation analysis failed to detect somatic mutation in HCC
cell lines and HCC samples.
Downregulation of tumor suppressor genes by epigenetic
mechanisms is a common phenomena in cancer (Cameron
et al., 1999). As somatic mutations were not frequent in
HCCs, we reasoned the downregulation of PTPRD due to
epigenetic silencing. First, we checked the methylation status
of PTPRD promoter in HCC samples. Six out of 27 tumors
(22.2%) displayed higher CpG methylation, suggesting that
promoter methylation of PTPRD is a frequent event in HCCs
(Fig. S3). Some non-tumoral counterparts of HCC samples
also displayed methylation, which can be explained by the
presence of precancerous lesions in these tissues. Moreover,
PTPRD expression was successfully restored in Hep3B cell
line after 5-AzaC and/or TSA treatments, providing an ad-
ditional layer of evidence for epigenetic silencing (Fig. 8).
Thus, our data suggest that PTPRD promoter hypermethy-
lation and histone deacetylation are associated with down-
regulation of the PTPRD.
Conclusions
PTPRD is homozygously deleted and epigenetically down-
regulated in human HCCs. Consequently, it seems reasonable
to hypothesize that PTPRD expression may have potential
clinical value, presumably as a prognostic marker. We antici-
pate that such questions will be a subject of future research with
studies in larger samples. Compelling evidence that is present
in other organ systems for a role of PTPRD inactivation
strengthen the hypothesis suggesting PTPRD as a strong
candidate for a tumor suppressor gene in HCC.
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